Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Int J Cancer. 2018 Sep 21;143(10):2400–2408. doi: 10.1002/ijc.31660

Table 1.

Summary of the two validated SNPsin the toll-like receptor signaling pathway geneIRAK2

SNP Allelea Gene PLCO (n=1185) Harvard (n=984) Meta-analysis Regulo meDB SNP info
EAF HR (95%CI)b Pb EAF HR (95%CI)c Pc Phetd I2 HR (95%CI)e Pe
rs779901 C/T IRAK2 0.14 0.78 (0.67-0.91) 0.001 0.15 0.84 (0.72-0.98) 0.031 0.47 0 0.81 (0.73-0.90) 1.08×10−4 4 no
rs779903 G/A IRAK2 0.14 0.78 (0.67-0.91) 0.001 0.15 0.84 (0.72-0.98) 0.032 0.47 0 0.81 (0.73-0.90) 1.09×10−4 no data no

Abbreviations: SNP, single-nucleotide polymorphism; TLR, toll-like receptor; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval.

a

Reference allele/effect allele;

b

Adjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3,PC4 in the PLCO dataset;

c

Adjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3 in the Harvard dataset;

d

Phet: P value for heterogeneity by Cochrane’s Q test;

e

Meta-analysis in the fix-effects model.

*

All the tests of the proportional hazards assumption for the validated SNPs in PLCO and Harvard studies were not statistically significant (P> 0.05).